Targeting the Transferrin Receptor to Develop Erythropoietin for Alzheimer’s Disease

Authors

Rachita K. Sumbria, Chapman UniversityFollow

Document Type

Article

Publication Date

6-19-2020

Abstract

"Alzheimer’s disease (AD) is the sixth leading cause of death in the United States with approximately 5.8 million Americans currently living with AD. Due to the lack of a disease modifying treatment for AD and the aging baby boomer generation, this number is projected to grow to 13.8 million by 2050 (Gaugler et al., 2019). Amyloid-beta (Aβ) plaque accumulation, one of the major pathological hallmarks of AD, can begin > 20 years before clinical symptoms of AD. By the time AD is clinically diagnosed, neuronal loss and neuropathological lesions (Aβ plaques and tau tangles) have already occurred in many brain regions (Gaugler et al., 2019). AD dementia correlates highly with neuronal loss, and therefore, reduction of neuropathological lesions in the AD brain at the time of clinical diagnosis alone cannot reverse AD dementia. We propose that a therapy that combines a reduction of neuropathological lesions of AD along with neuronal repair and neurogenesis may be required to treat AD dementia."

Comments

This article was originally published in Neural Regeneration Research, volume 15, issue 12, in 2020. https://doi.org/10.4103/1673-5374.284994

Recommended Citation

Sumbria RK. Targeting the transferrin receptor to develop erythropoietin for Alzheimer’s disease. Neural Regen Res. 2020;15(12):2251-2252. https://doi.org/10.4103/1673-5374.284994

Copyright

Medknow Publications

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.